BioSpace News Archive

Research may pinpoint way to save lives of approximately 20 percent of all COVID patients

IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe COVID-19 pneumonia

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial vaginosis. DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% being evaluated as a one-time, vaginally-administered treatment for bacterial vaginosis

Nascent Biotech, Inc. (OTCQB: NBIO) , today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.” An

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present an update on Company progress at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020 at 1:00pm E.T. using a virtual platform. A live webcast of the pr

Lead product candidate ONS-5010 / LYTENAVA TM (bevacizumab-vikg) has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications Topline results from NORSE 1, the Company’s first registration clinical trial evaluating ONS-5010 and providing clinical experience and initial safety and efficacy data, are expected in August 2020 NORSE 2 has enrolled 204 of 220 planned patients and is expected to complete enrollment no later than Augus

Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat and host investor meetings at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020 at 9:30 a.m. ET. About Replimune Replimune G

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the BMO 2020 Prescriptions for Success Healthcar

The UCSF Rosenman Institute is proud to announce the 2020 cohort of the Rosenman Innovators, a group of early-stage companies chosen for their innovative technologies and patient impact.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of